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Under physiological conditions, lymphatic vessels are thought to be absent from the
central nervous system (CNS), although they are widely distributed within the rest of
the body. Recent work in the eye, i.e., another organ regarded as alymphatic, revealed
numerous cells expressing lymphatic markers. As the latter can be involved in the
response to pathological conditions, we addressed the presence of cells expressing
lymphatic markers within the spinal cord by immunohistochemistry. Spinal cord of
young adult Fisher rats was scrutinized for the co-expression of the lymphatic markers
PROX1 and LYVE-1 with the cell type markers Iba1, CD68, PGP9.5, OLIG2. Rat skin
served as positive control for the lymphatic markers. PROX1-immunoreactivity was
detected in many nuclei throughout the spinal cord white and gray matter. These
nuclei showed no association with LYVE-1. Expression of LYVE-1 could only be
detected in cells at the spinal cord surface and in cells closely associated with blood
vessels. These cells were found to co-express Iba1, a macrophage and microglia
marker. Further, double labeling experiments using CD68, another marker found in
microglia and macrophages, also displayed co-localization in the Iba1+ cells located
at the spinal cord surface and those apposed to blood vessels. On the other hand,
PROX1-expressing cells found in the parenchyma were lacking Iba1 or PGP9.5, but
a significant fraction of those cells showed co-expression of the oligodendrocyte
lineage marker OLIG2. Intriguingly, following spinal cord injury, LYVE-1-expressing cells
assembled and reorganized into putative pre-vessel structures. As expected, the rat
skin used as positive controls revealed classical lymphatic vessels, displaying PROX1+
nuclei surrounded by LYVE-1-immunoreactivity. Classical lymphatics were not detected
in adult rat spinal cord. Nevertheless, numerous cells expressing either LYVE-1 or
PROX1 were identified. Based on their localization and overlapping expression with
Iba1, the LYVE-1+ cell population likely represents a macrophage subpopulation, while
a significant fraction of PROX1+ cells belong to the oligodendrocytic lineage based
on their distribution and the expression of OLIG2. The response of these LYVE-1+
and PROX1+ cell subpopulations to pathological conditions, especially in spinal cord
inflammatory conditions, needs to be further elucidated.
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INTRODUCTION
Two crucial roles are carried out by the lymphatic system:
(1) fluid homeostasis via the drainage of extracellular
fluid; and (2) immune defense through the transport of
antigens and immune cells to the lymph nodes (Alitalo,
2011; Card et al., 2014). To fulfill these functions, the
lymphatic system is widespread throughout the human
body (Breslin, 2014). Nevertheless, a few tissues, such as
the (inner) eye (Streilein, 2003) and the central nervous
system (CNS; Ransohoff and Engelhardt, 2012), lack a
‘‘classical’’ lymphatic system and are therefore considered
to be alymphatic. The epithet ‘‘classical’’ refers to the presence
of vessels with a lymphatic phenotype, i.e., with endothelial
cells expressing the surface receptors VEGFR3 or LYVE-1
and membrane bound components, such as podoplanin, or
transcription- factors, such as PROX1 or FOXC2 (Banerji
et al., 1999; Jackson et al., 2001; Sleeman et al., 2001; Jackson,
2007).
Over the last decades, research of the lymphatic system
underwent a tremendous boost based on the introduction
of these aforementioned markers. While identification
of lymphatics within a tissue remains challenging due
to the small caliber of the vessels and their structural
similarity with small-caliber blood vessels, the markers
introduced now allow reliable identification (Sleeman
et al., 2001). The crux with lymphatic markers however
is that no exclusive marker has been identified so far
(Sleeman et al., 2001) since most lymphatic markers are
also expressed on cells other than lymphatic endothelium
(Matsui et al., 1999; Schroedl et al., 2008). Therefore,
for the unequivocal identification of lymphatics, there
is a consensus that a combination of several markers is
necessary, as recently stated for the inner eye (Schroedl
et al., 2014) or under pathological conditions (Van der
Auwera et al., 2006). Hence, we chose for this study
the combination of the transcription factor PROX1, a
homeo-box protein that retains its activity in nuclei of
lymphatic endothelium in adulthood (Wigle and Oliver,
1999; Wilting et al., 2002) and LYVE-1, a membrane-bound
glycoprotein and one of the best characterized markers of
lymphatic endothelium (Jackson, 2004; Baluk and McDonald,
2008).
Being part of the CNS, which is considered to be alymphatic,
the existence of structures or cells expressing lymphatic
markers has not been thoroughly investigated within the spinal
cord. The characterization of these putative lymphatic cells
is particularly relevant for repair mechanisms considering
that lymphatic cells can organize into a lymphatic system
during pathological processes (Paavonen et al., 2000; Kerjaschki
et al., 2004; Maruyama et al., 2005; Zumsteg et al., 2009;
Tammela and Alitalo, 2010; Kerjaschki, 2014; Tempfer et al.,
2015).
In this study, we scrutinize with histological methods the
presence of potential lymphatic system or cells expressing
lymphatic markers in the healthy, as well as the injured, adult rat
spinal cord.
MATERIALS AND METHODS
Specimens
All experiments were performed in conformity with the Directive
(2010/63/EU) of the European Parliament and of the Council and
were approved by the national animal health commission (Land
Salzburg, Referat Gesundheitsrecht und Gesundheitsplanung
Referat 9/01). Female Fisher 344 rats of approximately 3 months
of age were used for this study. For histological analysis,
rats received an overdose of anesthetics (ketamine/xylazine/
acepromazine; i.p.) prior to transcardial perfusion with NaCl
0.9% followed by phosphate buffered saline (PBS) containing
4% formaldehyde. The spinal cord and skin samples from the
thigh were dissected, further fixed by immersion (1 h, room
temperature, RT) and rinsed in PBS. Spinal cord and skin
samples were transferred into PBS containing 15% sucrose (12 h
at 4◦C), embedded in tissue embedding medium (Slee Technik,
Mainz, Germany) and frozen using liquid nitrogen-cooled
methylbutane and stored at−20◦C until further processing.
Spinal Cord Contusion Injury (SCI)
Rats were anesthetized using 1.6% Isoflurane-oxygen mix.
For analgesia, 0.03 mg/kg bodyweight (bw) Buprenorphine
(Bupaqr, 0.3 mg/mL, Richterpharma, Wels, Austria) was
injected sub-cutaneous (SC) 30 min prior to surgery. To
prevent hypothermia, body temperature was maintained by
a rectal sensor-coupled to a heating pad. Heart frequence
and oxygen saturation was monitored throughout the whole
surgical procedures (SomnoSuiter, KENT). During surgery,
the dorsal aspect of the vertebra at thoracic level 8 was
removed to expose the dura mater and the spinal cord.
Contusion was performed using an Infinite Horizon impactor
(IH-Impactorr, Precision Systems and Instrumentation, LLC
with a force of 200 kdyn with immediate withdrawal). After
that the absence of bleeding has been confirmed, paravertebral
muscles were sutured and the skin was closed using a skin
stapler. To prevent pain and infections after surgery, 1–2 mg/kg
bw Meloxicam (Metacamr 5 mg/ml) and 10 mg/kg bw
Enrofloxacin (Baytrilr 25 mg/ml) was injected SC daily for
5 days. Additionally, 0.01 mg/kg bw Buprenorphine injected SC
twice a day for 2 days post surgery. As bladder function was
impaired after SCI, bladder was manually voided 2–3 times per
day. Perfusion for histological analysis was performed 14 days
post-lesion.
Immunohistochemistry
Spinal cord and skin samples were sectioned with a cryostat (HM
550, Microm, Walldorf, Germany) in serial sections of 16 µm,
collected on adhesion slides (Superfrost Plus; Thermo Scientific,
Wien Austria) and air-dried for 1 h at RT. Sections were rinsed
5 min in Tris-buffered saline (TBS; Roth, Karlsruhe, Germany)
and incubated for 1 h at RT in TBS containing 5% donkey serum
(Sigma-Aldrich,Wien, Austria), 1% bovine serum albumin (BSA;
Sigma-Aldrich), and 0.5% Triton X-100 (Merck, Darmstadt,
Germany). Sections were then rinsed for 5 min in TBS and
further incubated for single and double immunohistochemistry
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with the primary antibodies (Table 1) diluted in TBS, containing
1% BSA and 0.5% Triton X-100, for 12 h at RT. Sections
were rinsed four times for 5 min in TBS and the primary
antibodies visualized by corresponding Alexa488-, or Alexa555-
conjugated antibodies (Invitrogen, Karlsruhe, Germany) diluted
1:1000 in TBS, containing 1% BSA and 0.5% Triton X-100
(1 h at RT). Subsequently, the sections were rinsed 5 min
in TBS followed by a 10 min nuclear labeling with 4′,6-
Diamidino-2 phenylindole dihydrochloride (DAPI, 0.25 µg/mL;
VWR, Vienna, Austria). Finally, sections were rinsed three
times for 5 min in PBS and embedded in TBS-glycerol
(1:1 at pH 8.6).
Rat skin sections were used to validate the LYVE-1 and
PROX1 primary antibodies. Additionally, to avoid possible
cross-reactivity in experiments involving two or more primary
antibodies, successive incubations have been performed (i.e.,
primary and secondary antibodies for epitope one, followed by
incubation with primary and secondary antibodies for epitope
two). Negative controls were performed by omission of the
primary antibodies during incubation and resulted in absence of
immunoreactivity.
Documentation
Micrographs of immunohistostainings were acquired using a
confocal laser scanning unit (Axio ObserverZ1 attached to
LSM710, Zeiss, Göttingen, Germany; ×20 dry or ×40 and
×60 oil immersion objektive lenses, with numeric apertures
0.8, 1.30, and 1.4, respectively; Zeiss). All images presented
here consist of confocal images in single optical section
mode. Negative controls were recorded with identical laser
settings as used for documentation of corresponding primary
antibodies.
RESULTS
In the rat adult spinal cord, PROX1-immunoreactivity was
detected in numerous nuclei evenly distributed throughout
the gray and white matter. Nuclei of the central canal
lacked PROX1-immunoreactivity (Figure 1A). Absence of
immunoreactivity was observed in the negative controls
(Figure 1B), whereas in rat skin, used as positive control,
PROX1-positive nuclei were bordering luminal structures
(Figure 1C). Detection of the lymphatic endothelial marker
LYVE-1 revealed numerous LYVE-1-expressing cells on the
surface of the spinal cord, surrounding the ventral spinal artery,
and following the sulcal arteries into the anterior median
sulcus (Figure 1D). Double labeling experiments demonstrated
that cells expressing LYVE-1 did not possess PROX1-positive
nuclei (Figure 1D). Corresponding negative controls were
lacking immunoreactivity (Figure 1E), whereas controls in rat
skin showed cells with PROX-1 positive nuclei surrounded by
LYVE-1 immunoreactivity (Figure 1F). Identical results were
obtained on the dorsal side of the spinal cord, i.e., LYVE-1-
immunoreactive cells were detected on the spinal cord surface
and also in association with vessels of the dorsal spinal arteries
entering the parenchyma (Figures 1G,H). Occasionally, PROX1-
immunoreactive nuclei were in close vicinity with LYVE-1+
structures, which likely reflected expression of single markers
in adjacent cells (Figure 1H). Nevertheless, the overwhelming
majority of LYVE-1-positive cells surrounding vessels lacked
PROX1 immunoreactivity (Figure 1I).
Double immunohistochemistry with LYVE-1 and Iba1
revealed a co-localization of both markers in cells located at
the spinal cord surface (Figure 2A). Within the spinal cord,
LYVE-1+/Iba1+ cells surrounding blood vessels were detected,
whereas cells within the spinal cord parenchyma solely displayed
immunoreactivity for Iba1 (Figures 2D,E). Cells displaying
immunoreactivity exclusively for LYVE-1 were not observed.
Double immunohistochemistry for CD68 and Iba1 revealed an
identical pattern, i.e., CD68+/Iba1+ cells were detected on the
spinal cord surface (Figure 2F), following the spinal cord arteries
(Figures 2F,G). Cells immunoreactive exclusively for CD68
were not observed. Corresponding negative controls ascertained
the absence of immunoreactivity (Figure 2B). In contrast, in
the rat skin positive controls, two distinct cell populations were
observed expressing either LYVE-1 or Iba1 without apparent
co-localization (Figure 2C).
To further characterize the PROX1+ cells within the
spinal cord, PROX1-immunohistochemistry was combined
with either Iba1, the pan-neuronal marker PGP9.5, or
the oligodendrocyte lineage marker OLIG2. These double
labeling experiments revealed that PROX1+ nuclei were
not associated with Iba1 (Figure 3A), while corresponding
controls showed absence of immunoreactivity (Figure 3B).
Similarly, PGP9.5-immunoreactivity was not associated with
PROX1+ nuclei in both small- and large-sized neurons
(Figure 3C). Corresponding negative controls were not
immunoreactive (Figure 3D). In contrast, the combination
of PROX1 and OLIG2 revealed extensive co-localization
of both markers in nuclei throughout the spinal cord
TABLE 1 | Primary antibodies used in this study.
Markers Symbols Hosts Company Dilution
Prospero homeobox protein 1 PROX1 Mouse Acris; Herford, Germany 1:500
Lymphatic vessel endothelial hyaluronan receptor 1 LYVE-1 Rabbit Acris; Herford, Germany 1:50
Cluster of differentiation 68 CD68 Rabbit Abcam; Cambridge, UK 1:500
Ionized calcium-binding adapter molecule 1 Iba1 Goat Wako Chemicals; Neuss, Germany 1:500
Protein-gene product 9.5 PGP9.5 Guinea pig Merck Millipore; Vienna, Austria 1:500
Oligodendrocyte transcription factor 2 OLIG2 Rabbit Merck Millipore; Vienna, Austria 1:300
Major histocompatibility complex class II MHCII Mouse Abcam; Cambridge, UK 1:250
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FIGURE 1 | (A–C) In cross sections of the spinal cord, PROX1-immunoreactivity (red) was detected in numerous nuclei (DAPI, blue) throughout the gray and white
matter without preference, as indicated by purple mixed color (A), whereas negative controls revealed absence of immunoreactivity (B). Asterisk (A,B) indicates
ventral spinal artery, arrow (A,B) indicates the central canal. Controls in cross sections of rat skin (C) revealed nuclear Prox1 immunoreactivity as in (A).
(D–F) Double-immunohistochemistry of PROX1 (red) and LYVE-1 (green) reveals LYVE-1+ cells lacking PROX1-immunoreactivity on the surface of the spinal cord
and following the anterior sulcal arteries (D). Immunoreactivity was absent in negative controls (E). Asterisk in (D,E) indicates ventral spinal artery. Skin controls
revealed PROX1+ nuclei surrounded by LYVE-1-immunoreactivity (F). Blue: DAPI. (G–I) Double-immunohistochemistry of PROX1 (red) and LYVE-1 (green) reveals
LYVE-1+ cells on the surface of the posterior spinal cord lacking PROX1-immunoreactivity (G), following the posterior spinal arteries (arrowhead). While occasionally
cells were detected with apparent association of PROX1 and LYVE-1 (arrow in H), the majority of cells displayed immunoreactivity for LYVE-1 only (arrowheads in
H,I). (H) represents magnification of the boxed area in (G). Blue: DAPI.
(Figure 3E). Characterization in five randomly chosen
micrographs of approximately 200 nuclei expressing either
marker revealed that 46% were PROX1+/OLIG2+, whereas
42% showed immunoreactivity for OLIG2 only and 12%
displayed immunoreactivity for PROX1 only. PROX1/OLIG2
immunoreactivity was absent in corresponding negative controls
(Figure 3F).
Preliminary investigation in lesioned spinal cord revealed cell
debris and cells accumulation within the lesion site. Many cells
displayed immunoreactivity for CD68 (Figure 4A), while
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FIGURE 2 | (A–C) Double-immunohistochemistry of LYVE-1 (red) and Iba1 (green) reveals LYVE-1+/Iba1+ cells on the surface of the spinal cord, following the
anterior sulcal arteries (A), whereas negative controls revealed absence of immunoreactivity (B). Asterisk in (A,B) indicates ventral spinal artery. Skin controls revealed
DAPI+ nuclei (blue) surrounded by LYVE-1-immunoractivity (C), and dispersed cells showing immunoreactivity for Iba1 only. (D,E) Within the spinal cord parenchyma,
double immunohistochemistry for LYVE-1 (red) and Iba1 (green) reveals cells co-localizing for both markers (arrows in D,E) bordering spinal cord blood vessels
(arrowheads in D,E), whereas the majority of cells displayed immunoreactivity for Iba1 only. Blue: DAPI. (F,G) Double-immunohistochemistry of CD68 (red) and Iba1
(green) reveals CD68+/Iba1+ cells on the surface of the spinal cord (F), and on cells bordering spinal cord blood vessels (arrows in G). (G) Higher magnification of
boxed area in (F). Blue: DAPI.
a subpopulation of CD68+ cells was also immunoreactive
for MCHII (Figure 4A). Iba1-immunoreactive cells
were interspersed between CD68+/MHCII+ cells (Figure 4A).
The amount of CD68-immunoreactive cells decreases
towards the periphery of the lesion site, and similarly
Iba1+ cells were less frequently detected. Within the lesion
site, LYVE-1+ cells assembled in structures that were not
observed in the unlesioned tissue (Figures 4B,C). These
LYVE-1+ structures appeared organized (Figure 4C), where
associated with elongated nuclei, and displayed vessel-like
formation (Figures 4C,D). Double immunohistochemistry
with LYVE-1 and PROX1 revealed that the majority of
LYVE-1 immunoreactive structures were not associated
with PROX1-poitive nuclei (Figure 4E). However, in few
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FIGURE 3 | (A,B) Double-immunohistochemistry of PROX1 (red) and Iba1 (green) reveals that PROX1 positive nuclei (purple mixed color) are not associated with
Iba1-positive cells (A), whereas negative controls lack immunoreactivity (B). Blue: DAPI. (C,D) Double-immunohistochemistry of PROX1 (red) and the pan-neuronal
marker PGP9.5 (green) reveals that PROX1-positive nuclei (purple mixed color) are not associated with neurons of the spinal cord (C; arrowheads point to small
neurons, open arrowheads outline a faint immunoreactive large neuron), whereas negative controls lack immunoreactivity (D). Blue: DAPI. (E,F) Double-
immunohistochemistry of PROX1 (green) and OLIG2 (red) reveals co-localized nuclei (E; yellow mixed color, open arrowheads), whereas some nuclei display
OLIG2-immunoreactivity only (E; arrowheads). Immunoreactivity was absent in corresponding negative controls (F).
instances, PROX1-positive nuclei were closely related to LYVE-1
immunoreactive structures (Figure 4F).
DISCUSSION
The dominant opinion in current textbooks considers the CNS
as an alymphatic environment (Iliff and Nedergaard, 2013).
However, with the availability of lymphatic markers, this dogma
has been recently revisited and challenged (Aspelund et al.,
2015; Louveau et al., 2015; Wood, 2015). Therefore, we
investigated adult rat spinal cord for the expression of
components specific for lymphatic endothelium, namely
the membrane bound glycoprotein LYVE-1 in combination
with the transcription factor PROX1. LYVE-1 as a marker
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FIGURE 4 | (A) Within the lesion site, many cells were detected displaying immunoreactivity for CD68 (red), a subpopulation of which co-localized for MHCII (blue,
arrowheads), while Iba1-immunoreactive cells (green) were intermingling. (B,C) Close to the lesion center (asterisks), organized LYVE-1 immunoreactive structures
(green) were detected (C, arrowheads; magnification of boxed area in B), displaying vessel-like appearance. DAPI: gray. (D) Another example of vessel-like structure
expressing LYVE-1. DAPI: gray. (E,F) Double immunohistochemistry of LYVE-1 (green) and PROX1 (red) revealed that the majority of LYVE-1 immunoreactive
structures were not associated with PROX1-positive nuclei (E). In few instances, PROX1 positive nuclei were detected closely associated with LYVE-1
immunoreactive structures (F, arrowheads), while other nuclei in proximity were lacking PROX1 (F, open arrowheads).
for lymphatic endothelium was first identified in 1999 by
Banerji et al. (1999). However, its expression is not exclusive
for lymphatics, since it is also detected among others on
liver sinusoids (Mouta Carreira et al., 2001), pulmonary
(Favre et al., 2003) and renal glomerular capillaries (Lee
et al., 2011) and its expression pattern may also change
along the lymphatic vascular tree (Baluk and McDonald,
2008).
The function of LYVE-1 in cells of these various systems is
still not fully understood (Jackson, 2009). On the other side,
PROX1 is a homeobox transcription factor and a key player in the
development of many organ systems, such as the enterohepatic
system or heart (Oliver et al., 1993; Sosa-Pineda et al., 2000). In
the CNS, PROX1 is known as a critical regulator of neurogenesis
and neuronal differentiation (reviewed in Stergiopoulos et al.,
2014). In nuclei of lymphatic endothelial cells, PROX1 expression
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persists into adulthood in physiological as well as in pathological
conditions (Wilting et al., 2002). Here, PROX1 is considered to be
a master gene (Hong and Detmar, 2003) in lymphatic endothelial
progenitor cells controlling the expression of other lymphatic
markers (for review, see Yang and Oliver, 2014).
Although we could readily detect these two markers
closely associated in lymphatic endothelial cells of the skin,
our lymphatic control tissue, our study demonstrated the
absence of PROX1+/LYVE-1+ cells in the spinal cord. On the
other hand, we detected numerous cells expressing either of
these markers, however, under physiological conditions, these
were not associated with lymphatic vessel-like structures. The
LYVE-1+ cells were found at the surface of the spinal cord
or closely located to spinal cord blood vessels. These LYVE+
cells co-localized with the macrophage and microglia markers
Iba1, and most likely also CD68, as observed by the almost
overlap of the latter with Iba1-immunoreactivity. This marker
combination, together with the localization in vicinity to blood
vessels highly suggests that this cell population represents
macrophages.
Indeed, brain macrophages are mainly situated close to
cerebral blood vessels under physiological conditions (Bogie
et al., 2014) and LYVE-1 expression in macrophages is well
established in other systems (Schledzewski et al., 2006; Cho
et al., 2007; Schroedl et al., 2008). While macrophages play
an important role during pathological processes (Shechter and
Schwartz, 2013), the role of the LYVE-1+ macrophage sub-
population in the spinal cord in physiological and pathological
conditions remains to be elucidated. Following spinal cord
contusion injury, we could detect a re-organization and
redistribution of cells expressing LYVE-1 within the lesioned
parenchyma. Some of these cells reorganized in structures
resembling putative pre-vessels (Figure 4). Therefore, following
lesion, there is a solid evidence to reconsider the possibility of
lymphatics within the spinal cord, and most likely also within the
brain.
PROX1+ cells were found widespread throughout the spinal
cord parenchyma. These PROX1-positive nuclei were neither
detected in association with the microglia/macrophage marker
Iba1, nor with the pan-neuronal marker PGP9.5, thus ruling out
that they represented microglia or neurons, respectively. Instead,
PROX1+ nuclei were co-localized with the oligodendrocyte
lineage marker OLIG2. The co-existence of these two markers
within a cell population is particularly puzzling since Olig2
and PROX1 have been reported to reciprocally suppress the
expression of each other during development and in forced-
expression experiments (Kaltezioti et al., 2014; Stergiopoulos
et al., 2014). Nevertheless, in a study addressing the gene
expression pattern found in the various cell populations of
the CNS, Cahoy et al. (2008) found that Olig2 and PROX1
are enriched in the oligodendroglial lineage. Moreover, the
expression of PROX1 was five times higher in myelin-producing
oligodendrocytes as compared to oligodendrocyte precursor cells
(OPCs). Hence, the PROX1+/Olig2+ cell population detected in
the spinal cord probably consists of mature oligodendrocytes.
Whether the small percentage of cells expressing solely PROX1
constitutes a distinct population, or a population with low Olig2
expression, remains to be deciphered.
With this study, we confirmed the assumption that classical
lymphatic vessels are absent from the healthy adult rat spinal
cord. Nevertheless, recent data generated under pathological
conditions suggested the development of lymphatic structures
in otherwise alymphatic environments, as seen for example in
cornea (Cursiefen et al., 2002) or tendon lesions (Tempfer et al.,
2015). On the other hand, the existence of structures capable of
fulfilling lymphatic vessel-like functions, as recently described
for e.g., the Schlemm’s Canal of the eye (Aspelund et al., 2014),
remains to be demonstrated in the spinal cord. The response
of the LYVE-1 positive macrophages observed following spinal
cord lesion needs to be further investigated as they may be
the prerequisite for the formation of lymphatic-like structures
(Maruyama et al., 2005; Alitalo, 2011; Ran and Montgomery,
2012; Kerjaschki, 2014).
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